1. Home
  2. NUVB vs RDW Comparison

NUVB vs RDW Comparison

Compare NUVB & RDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • RDW
  • Stock Information
  • Founded
  • NUVB 2018
  • RDW 2020
  • Country
  • NUVB United States
  • RDW United States
  • Employees
  • NUVB N/A
  • RDW N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • RDW Military/Government/Technical
  • Sector
  • NUVB Health Care
  • RDW Industrials
  • Exchange
  • NUVB Nasdaq
  • RDW Nasdaq
  • Market Cap
  • NUVB 1.1B
  • RDW 1.2B
  • IPO Year
  • NUVB N/A
  • RDW N/A
  • Fundamental
  • Price
  • NUVB $3.28
  • RDW $7.85
  • Analyst Decision
  • NUVB Strong Buy
  • RDW Buy
  • Analyst Count
  • NUVB 6
  • RDW 8
  • Target Price
  • NUVB $8.17
  • RDW $16.56
  • AVG Volume (30 Days)
  • NUVB 6.7M
  • RDW 3.9M
  • Earning Date
  • NUVB 11-05-2025
  • RDW 11-05-2025
  • Dividend Yield
  • NUVB N/A
  • RDW N/A
  • EPS Growth
  • NUVB N/A
  • RDW N/A
  • EPS
  • NUVB N/A
  • RDW N/A
  • Revenue
  • NUVB $14,355,000.00
  • RDW $261,353,000.00
  • Revenue This Year
  • NUVB $332.80
  • RDW $34.83
  • Revenue Next Year
  • NUVB $360.12
  • RDW $41.86
  • P/E Ratio
  • NUVB N/A
  • RDW N/A
  • Revenue Growth
  • NUVB 900.35
  • RDW N/A
  • 52 Week Low
  • NUVB $1.54
  • RDW $6.22
  • 52 Week High
  • NUVB $4.09
  • RDW $26.66
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 58.18
  • RDW 33.32
  • Support Level
  • NUVB $3.20
  • RDW $8.08
  • Resistance Level
  • NUVB $3.41
  • RDW $9.60
  • Average True Range (ATR)
  • NUVB 0.27
  • RDW 0.46
  • MACD
  • NUVB -0.03
  • RDW 0.22
  • Stochastic Oscillator
  • NUVB 33.55
  • RDW 4.28

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About RDW Redwire Corporation

Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.

Share on Social Networks: